News

Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution. They negotiate rebates, design formularies, adjudicate claims, and steer patient adherence. Modern artificial intelligence (AI) is designed to compress each of these high-volume, rules-driven processes. As autonomous prior authorization, real-time formulary optimization, and AI-driven rebate analytics scale, the Big Three PBMs face a ... AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers

Shares of Humana (NYSE:HUM) are trading near $303 at midday Monday, slightly lower on the session after a flat open. The one-month picture, however, tells a very different story. Humana stock is up 48% over the past month, dwarfing peers in the managed care complex. That run has put Humana well ahead of UnitedHealth Group ... Humana Just Ripped 48% in a Month. Is It Outperforming Other Healthcare Stocks Like UnitedHealth and Cigna?

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

CI trades below the industry's forward P/E as Evernorth's growth, earnings beats and shareholder returns support its long-term outlook.

Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls

The Cigna Group recently reported first-quarter 2026 results, with sales of US$63,849 million, revenue of US$68,494 million, and net income of US$1,654 million, and raised its full-year adjusted EPS guidance to at least US$30.35 following these results. Alongside these figures, Cigna highlighted strong earnings per share growth from continuing operations, underscoring the contribution of its health services and insurance platforms to overall profitability. Now we’ll examine how Cigna’s...

Cigna has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

With a 5-year average dividend growth rate of 42.4%, The Cigna Group (NYSE:CI) is included among the 14 Best Dividend Stocks to Buy for Steady Growth. On May 5, Bernstein analyst Lance Wilkes raised the firm’s price recommendation on The Cigna Group (NYSE:CI) to $371 from $358. It reiterated an Outperform rating following the company’s quarterly […]

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...

Insight into Chris Davis (Trades, Portfolio)'s Strategic Moves in Q1 2026

The most significant insight currently obscured by CVS Health's (CVS) headline revenue growth is a high-stakes transition: the company is attempting to use a temporary surge in insurance profitability to outrun the structural margin pressures facing its pharmacy benefit management (PBM) business.

Investors were underwhelmed by the solid earnings posted by The Cigna Group ( NYSE:CI ) recently. Our analysis says...

With an upside potential of 20.18% as of May 3, The Cigna Group (NYSE:CI) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. The Cigna Group (NYSE:CI) is a global health company that provides insurance and related products and services. It operates through two segments: Evernorth Health Services and Cigna Healthcare. […]

CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.

Shares of health insurance company Cigna (NYSE:CI) fell 2.5% in the afternoon session after the company announced it will exit the Affordable Care Act (ACA) marketplace in 2027, which overshadowed a strong first-quarter earnings report.

Investors in The Cigna Group ( NYSE:CI ) had a good week, as its shares rose 2.6% to close at US$283 following the...

Health insurance company Cigna (NYSE:CI) announced better-than-expected revenue in Q1 CY2026, with sales up 4.7% year on year to $68.52 billion. Its non-GAAP profit of $7.79 per share was 2.4% above analysts’ consensus estimates.

The Cigna Group (NYSE:CI) reported a strong start to 2026 and raised its full-year adjusted earnings outlook following first-quarter results that management said exceeded expectations in key areas, while also announcing additional portfolio changes and providing an update on its leadership transitio

Moby summary of Cigna Corporation's Q1 2026 earnings call

CI beats Q1 EPS estimates as Evernorth revenues jump 9% despite rising pharmacy costs; 2026 EPS outlook lifted to at least $30.35.

Cigna raises 2026 profit outlook after a first-quarter beat, while exiting ACA plans and reviewing EviCore strategic options.

The move follows Aetna’s departure from the ACA market, which has seen significantly declining membership amid rising premium bills.

Is CI a good stock to buy? We came across a bullish thesis on The Cigna Group on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on CI. The Cigna Group’s share was trading at $279.92 as of April 20th. CI’s trailing and forward P/E were 12.62 and 9.23, respectively according to Yahoo Finance. […]

While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The company modestly raised its forecast for 2026 profits amid a shift in its drug pricing and CEO transition.